Free Trial
→ Every Starlink dish pays this stock (From Behind the Markets) (Ad)tc pixel
NASDAQ:LGVN

Longeveron Q3 2026 Earnings Date & Estimates

Longeveron logo
$2.66 +0.65 (+32.29%)
As of 02:15 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Longeveron is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, after market closes.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Longeveron in Q3 2026

Longeveron is expected to post earnings of -$1.70 per share on revenue of $800 thousand. In the same quarter a year earlier Longeveron reported -$3.90 per share on revenue of $137 thousand. Longeveron last reported on August 12, 2026, posting -$0.19 per share and beating the -$1.75 consensus estimate. Longeveron has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$1.70
Expected Revenue
$800 thousand
Prior-Year EPS
-$3.90
Prior-Year Revenue
$137 thousand
Expected Revenue Growth
+483.9%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.19 (Beat by +$1.56)
Last Quarter Revenue
$287 thousand
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Longeveron Q3 2026 Earnings FAQ

Longeveron (NASDAQ:LGVN) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Longeveron's Q3 2026 earnings conference call is scheduled for Tuesday, November 17, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Longeveron to post earnings of -$1.70 per share for Q3 2026.

The consensus revenue estimate for Longeveron is $800 thousand for Q3 2026.

Longeveron Earnings Headlines

Longeveron (LGVN) Projected to Announce Earnings on Tuesday
November 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31173216
Longeveron (NASDAQ:LGVN) Raised to Hold at Wall Street Zen
November 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31172870
Why Iran May Only Be the First Move
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen. No cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.tc pixel
November 10 at 1:00 AM  |  Behind the Markets (Ad)
Longeveron Announces Engagement of Lucid Capital Markets
October 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/28/3390289/0/en/longeveron-announces-engagement-of-lucid-capital-markets.html
Longeveron Inc. Retains Lucid Capital Markets to Explore Strategic Alternatives, Including Potential Business Combination
October 28, 2026  |  quiverquant.comQ
Longeveron Reports Fewer Cardiac Events In Phase 2b Heart Syndrome Trial After Primary Endpoint Miss
October 28, 2026  |  rttnews.comhttps://www.rttnews.com/3703668/longeveron-reports-fewer-cardiac-events-in-phase-2b-heart-syndrome-trial-after-primary-endpoint-miss.aspx
See More Longeveron Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Longeveron? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Longeveron and other key companies, straight to your email.

About Longeveron

Longeveron (NASDAQ:LGVN) is a clinical-stage biotechnology company focused on developing regenerative medicines for serious and life-threatening conditions. The company’s research centers on cell-based therapies intended to support tissue repair, reduce harmful inflammation and promote the body’s natural healing processes.

Longeveron’s lead investigational product is Lomecel-B, an allogeneic cell therapy derived from bone marrow obtained from healthy adult donors. The company has evaluated Lomecel-B in clinical programs addressing hypoplastic left heart syndrome, a rare congenital heart defect in infants, as well as Alzheimer’s disease and aging-related frailty. These uses remain investigational, and Lomecel-B has not been approved by the U.S. Food and Drug Administration for commercial use.

Founded in 2014 and headquartered in Miami, Florida, Longeveron conducts its development activities through clinical research programs in the United States and collaboration with medical and research institutions. The company is led by Chief Executive Officer Wa’el Hashad, who joined Longeveron after holding leadership positions in the biopharmaceutical industry.

View Longeveron Profile
Earnings Tools